Gain-of-function variants of JAK2 and STAT3 have been reported to be associated with IBD progression, and various small-molecule inhibitors of JAK have been shown to be efficacious in the treatment of IBD over the past years, especially for patients who are refractory to treatment with TNFα antagonists [42, 43]. Here, STAT3 is linked to inflammatory bowel disease.